Videos and Podcasts

9th Nov 21

Pharmaxis receives approval for phase 2 study of its cancer drug in liver cancer

Pharmaxis CEO Gary Phillips speaks to Proactive following the news an Investigational New Drug application for a trial of PXS‐5505 in hepatocellular carcinoma (HCC) patients has been cleared by the FDA. The IND was submitted by the University of Rochester Medical Center following positive pre‐clinical results reported in August.

Watch the interview here

28th Oct 21

Pharmaxis Quarterly Shareholder Update and Investor Presentation

Watch a recording of the Pharmaxis Ltd September Quarterly Shareholder Update by the chief executive officer Mr Gary Phillips on Thursday 28 October 2021.

Watch recording here.

5th Oct 21

Pharmaxis Welcomes Green Light to Progress to Phase 2 Bone Marrow Cancer Trial

Pharmaxis CEO Gary Phillips speaks to Proactive Investors following the news the Company has been cleared to progress its bone marrow cancer trial to a phase 2 dose expansion phase. It follows further positive results of data analysis from the phase 1c clinical trial of its drug PXS‐5505.

Watch the interview here.